EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

Mark J Levis iD, Mehdi Hamadani iD, Brent Logan iD, Richard J Jones, Anurag K Singh, Mark Litzow iD, John R Wingard iD, Esperanza B Papadopoulos, Alexander E Perl iD, Robert J Soiffer iD, Celalettin Ustun iD, Masumi Ueda Oshima iD und 28 weitere

Journal of Clinical Oncology · 20.05.2024 · 42 (15) · 1766-1775

DOI: 10.1200/jco.23.02474 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2024. Verfasst von Mark J Levis und 39 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University, Baltimore, MD. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Pyrazines, Aniline Compounds. Die Arbeit wurde bisher 244-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202 ) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P = .575). CONCLUSION Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcutePyrazinesAniline CompoundsHematopoietic Stem Cell TransplantationMutationHumansMaleFemaleMiddle AgedAdultAgedTandem Repeat SequencesYoung AdultNeoplasm, ResidualProtein Kinase InhibitorsMaintenance ChemotherapyGene Duplication

Substanzen

fms-Like Tyrosine Kinase 3PyrazinesAniline CompoundsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Johns Hopkins University, Baltimore, MD.
  • CIBMTR/Medical College of Wisconsin, Milwaukee, WI.
  • University of Kansas, Kansas City, KS.
  • Mayo Clinic, Rochester, MN.
  • University of Florida, Gainesville, FL.
  • Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Mark J Levis, Mehdi Hamadani, Brent Logan, Mark Litzow, John R Wingard, Alexander E Perl, Robert J Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K Waller, Melhem Solh, Asmita Mishra, Lori Muffly, Hee-Je Kim, Yuho Najima, Masahiro Onozawa, Arnon Nagler, Andrew H Wei, Nancy L Geller, Jason Hill, Stanley C Gill, Denise King, Steven M Devine, Mary M Horowitz, Yi-Bin Chen

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS

Zitieren

APA

Levis, M. J., Hamadani, M., Logan, B., Jones, R. J., Singh, A. K., Litzow, M., Wingard, J. R., Papadopoulos, E. B., Perl, A. E., Soiffer, R. J., Ustun, C., Ueda Oshima, M., Uy, G. L., Waller, E. K., Vasu, S., Solh, M., Mishra, A., Muffly, L., Kim, H. J., …, & BMT-CTN 1506/MORPHO Study Investigators (2024). Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. Journal of Clinical Oncology, 42(15), 1766-1775. https://doi.org/10.1200/jco.23.02474

Vancouver

Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. Journal of Clinical Oncology. 2024;42(15):1766-1775. doi:10.1200/jco.23.02474

BibTeX
@article{Levis2024,
  author = {Levis, Mark J and Hamadani, Mehdi and Logan, Brent and Jones, Richard J and Singh, Anurag K and Litzow, Mark and Wingard, John R and Papadopoulos, Esperanza B and Perl, Alexander E and Soiffer, Robert J and Ustun, Celalettin and Ueda Oshima, Masumi and Uy, Geoffrey L and Waller, Edmund K and Vasu, Sumithra and Solh, Melhem and Mishra, Asmita and Muffly, Lori and Kim, Hee-Je and Mikesch, Jan-Henrik and Najima, Yuho and Onozawa, Masahiro and Thomson, Kirsty and Nagler, Arnon and Wei, Andrew H and Marcucci, Guido and Geller, Nancy L and Hasabou, Nahla and Delgado, David and Rosales, Matt and Hill, Jason and Gill, Stanley C and Nuthethi, Rishita and King, Denise and Wittsack, Heather and Mendizabal, Adam and Devine, Steven M and Horowitz, Mary M and Chen, Yi-Bin and BMT-CTN 1506/MORPHO Study Investigators, BMT-CTN 1506/MORPHO Study Investigators},
  title = {Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {15},
  pages = {1766--1775},
  doi = {10.1200/jco.23.02474}
}
Kostenlos starten →